Search for "nitrogen-containing heterocycle" in Full Text gives 6 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2024, 20, 2114–2128, doi:10.3762/bjoc.20.182
Graphical Abstract
Figure 1: Resonance structures and reactivity of carbon monoxide.
Figure 2: Resonance structures and reactivity of isocyanides.
Scheme 1: Possible three pathways of the E• formation for imidoylation.
Scheme 2: Radical addition of thiols to isocyanides.
Scheme 3: Selective thioselenation and catalytic dithiolation of isocyanides.
Scheme 4: Synthesis of carbacephem framework.
Scheme 5: Sequential addition of (PhSe)2 to ethyl propiolate and isocyanide.
Scheme 6: Isocyanide insertion reaction into carbon-tellurium bonds.
Scheme 7: Radical addition to isocyanides with disubstituted phosphines.
Scheme 8: Radical addition to phenyl isocyanides with diphosphines.
Scheme 9: Radical reaction of tin hydride and hydrosilane toward isocyanide.
Scheme 10: Isocyanide insertion into boron compounds.
Scheme 11: Isocyanide insertion into cyclic compounds containing boron units.
Scheme 12: Photoinduced hydrodefunctionalization of isocyanides.
Scheme 13: Tin hydride-mediated indole synthesis and cross-coupling.
Scheme 14: 2-Thioethanol-mediated radical cyclization of alkenyl isocyanide.
Scheme 15: Thiol-mediated radical cyclization of o-alkenylaryl isocyanide.
Scheme 16: (PhTe)2-assisted dithiolative cyclization of o-alkenylaryl isocyanide.
Scheme 17: Trapping imidoyl radicals with heteroatom moieties.
Scheme 18: Trapping imidoyl radicals with isocyano group.
Scheme 19: Quinoline synthesis via aza-Bergman cyclization.
Scheme 20: Phenanthridine synthesis via radical cyclization of 2-isocyanobiaryls.
Scheme 21: Phenanthridine synthesis by radical reactions with AIBN, DBP and TTMSS.
Scheme 22: Phenanthridine synthesis by oxidative cyclization of 2-isocyanobiaryls.
Scheme 23: Phenanthridine synthesis using a photoredox system.
Scheme 24: Phenanthridine synthesis induced by phosphorus-centered radicals.
Scheme 25: Phenanthridine synthesis induced by sulfur-centered radicals.
Scheme 26: Phenanthridine synthesis induced by boron-centered radicals.
Scheme 27: Phenanthridine synthesis by oxidative cyclization of 2-aminobiaryls.
Beilstein J. Org. Chem. 2024, 20, 1988–2004, doi:10.3762/bjoc.20.175
Graphical Abstract
Scheme 1: Synthesis of triazolopyridinium salts [34-36].
Scheme 2: Synthesis of pyrazoles [37].
Scheme 3: Synthesis of indazoles from ketone-derived hydrazones [38].
Scheme 4: Intramolecular C(sp2)–H functionalization of aldehyde-derived N-(2-pyridinyl)hydrazones for the syn...
Scheme 5: Synthesis of pyrazolo[4,3-c]quinoline derivatives [40].
Scheme 6: Synthesis of 1,3,4-oxadiazoles and Δ3-1,3,4-oxadiazolines [41].
Scheme 7: Synthesis of 1,3,4-oxadiazoles [43].
Scheme 8: Synthesis of 2-(1,3,4-oxadiazol-2-yl)anilines [44].
Scheme 9: Synthesis of fused s-triazolo perchlorates [45].
Scheme 10: Synthesis of 1-aryl and 1,5-disubstitued 1,2,4-triazoles [49].
Scheme 11: Synthesis of 1,3,5-trisubstituted 1,2,4-triazoles [50].
Scheme 12: Alternative synthesis of 1,3,5-trisubstituted 1,2,4-triazoles [51].
Scheme 13: Synthesis of 5-amino 1,2,4-triazoles [55].
Scheme 14: Synthesis of 1-arylpyrazolines [58].
Scheme 15: Synthesis of 3‑aminopyrazoles [60].
Scheme 16: Synthesis of [1,2,4]triazolo[4,3-a]quinolines [61].·
Scheme 17: Synthesis of 1,2,3-thiadiazoles [64].
Scheme 18: Synthesis of 5-thioxo-1,2,4-triazolium inner salts [65].
Scheme 19: Synthesis of 1-aminotetrazoles [66].
Scheme 20: C(sp2)–H functionalization of aldehyde-derived hydrazones: general mechanisms.
Scheme 21: C(sp2)–H functionalization of benzaldehyde diphenyl hydrazone [68,69].
Scheme 22: Phosphorylation of aldehyde-derived hydrazones [70].
Scheme 23: Azolation of aldehyde-derived hydrazones [72].
Scheme 24: Thiocyanation of benzaldehyde-derived hydrazone 122 [73].
Scheme 25: Sulfonylation of aromatic aldehyde-derived hydrazones [74].
Scheme 26: Trifluoromethylation of aromatic aldehyde-derived hydrazones [76].
Scheme 27: Electrooxidation of benzophenone hydrazones [77].
Scheme 28: Electrooxidative coupling of benzophenone hydrazones and alkenes [77].
Scheme 29: Electrosynthesis of α-diazoketones [78].
Scheme 30: Electrosynthesis of stable diazo compounds [80].
Scheme 31: Photoelectrochemical synthesis of alkenes through in situ generation of diazo compounds [81].
Scheme 32: Synthesis of nitriles [82].
Scheme 33: Electrochemical oxidation of ketone-derived NH-allylhydrazone [83].
Beilstein J. Org. Chem. 2020, 16, 628–637, doi:10.3762/bjoc.16.59
Graphical Abstract
Figure 1: Chemical structures of the target diazine-based surrogates for the central core of panobinostat.
Figure 2: Docking pose for panobinostat and panobinostat derivatives in the HDAC8 receptor. (a) Overlay of al...
Figure 3: General building blocks for the visualized targets.
Scheme 1: Reaction conditions: a) MeOH, H2SO4 (5 drops), MS 4 Å (2 pieces), 68 °C, 8 h, 81%; b) DIBAL-H (1.2 ...
Scheme 2: Reaction conditions: a) boronic acid 15 (1.3 equiv), PdCl2(PPh3)2 (0.1 equiv), dioxane/H2O (3:1), Na...
Scheme 3: Reaction conditions: a) 5-bromo-2-chloropyrimidine (1 equiv), ethyl formate (1.5 equiv), THF (20 mL...
Scheme 4: Reaction conditions: a) boronic acid 15 (1.3 equiv), PdCl2(PPh3)2 (0.1 equiv), dioxane/H2O (8:2, Na2...
Beilstein J. Org. Chem. 2017, 13, 1407–1412, doi:10.3762/bjoc.13.137
Graphical Abstract
Figure 1: Main synthetic strategies towards heterocyclic cores of D-series GE2270 and our present one.
Scheme 1: Synthesis of trithiazolylpyridine 9. Reaction conditions: a) Pd(OAc)2 (5 mol %), CyJohnPhos (10 mol...
Scheme 2: Synthesis of chiral thioamide 16. Reaction conditions: a) SnCl2∙2H2O, dioxane/H2O (1:3), 0 °C to rt...
Scheme 3: Synthesis of the heterocyclic core of the D-series GE2270. Reaction conditions: a) TBDMSOTf, NEt3, ...
Beilstein J. Org. Chem. 2012, 8, 514–521, doi:10.3762/bjoc.8.58
Graphical Abstract
Figure 1: Structure of trehalose (1), validoxylamine A (2), 1-thiatrehazolin (3), trehalostatin (4), casuarin...
Figure 2: Structure of nojirimycin-based (7, 8) and pyrrolidine-based (9) leads.
Figure 3: Structures of potential inhibitors 10–21.
Scheme 1: Synthesis of nojirimycin-based inhibitors 10,12 and 13. Reagents and conditions: (a) H2, Pd/C, NH4O...
Scheme 2: Synthesis of pyrrolidine derivatives 14, 16, 17 and 19. Reagents and conditions: (a) H2, Pd(OH)2/C,...
Scheme 3: Synthesis of pyrrolidines 20 and 21. Reagents and conditions: (a) H2, Pd/C, MeOH, HCl; (b) octanal,...
Figure 4: Histogram of the inhibitory activity of compounds 7–10, 12–14, 16 and 20. Derivatives 10, 14 and 16...
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).